Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2013, Article ID 976034, 8 pages
http://dx.doi.org/10.1155/2013/976034
Research Article

Validation and Application of a New Reversed Phase HPLC Method for In Vitro Dissolution Studies of Rabeprazole Sodium in Delayed-Release Tablets

Quality Assurance Department, ACI Ltd., Narayanganj 1400, Bangladesh

Received 21 May 2013; Revised 18 July 2013; Accepted 19 July 2013

Academic Editor: Josep Esteve-Romero

Copyright © 2013 Md. Saddam Nawaz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Pantoflickova, G. Dorta, M. Ravic, P. Jornod, and A. L. Blum, “Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 12, pp. 1507–1514, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. C. A. Desai and B. D. Samant, “Rabeprazole,” Journal of Postgraduate Medicine, vol. 48, no. 1, pp. 80–81, 2002. View at Google Scholar · View at Scopus
  3. C. V. Garcia, C. S. Paim, and M. Steppe, “New liquid chromatographic method for determination of rabeprazole sodium in coated tablets,” Journal of AOAC International, vol. 87, no. 4, pp. 842–846, 2004. View at Google Scholar · View at Scopus
  4. U. M. Karra and S. Yarkala, “A simple and validated reverse phase HPLC method for the determination of rabeprazole in pharmaceutical dosage forms,” E-Journal of Chemistry, vol. 7, no. 2, pp. 569–577, 2010. View at Google Scholar · View at Scopus
  5. R. Buchireddy, K. Mukkanti, P. Srinivasulu, and K. S. V. Srinivas, “A validated, stability-indicating, LC method for rabeprazole sodium,” Chromatographia, vol. 68, no. 3-4, pp. 275–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. P. R. Battu and M. S. Reddy, “Development and validation of RP-HPLC for the rabeprazole sodium in pharmaceutical formulations and human plasma,” Asian Journal of Research in Chemistry, vol. 2, pp. 49–51, 2009. View at Google Scholar
  7. Y. S. Rhee, C. W. Park, Y. S. Shin, S. H. Kam, K. H. Lee, and E. S. Park, “Application of instrumental evaluation of color for the pre-formulation and formulation of rabeprazole,” International Journal of Pharmaceutics, vol. 350, no. 1-2, pp. 122–129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. V. G. Cássia, S. N. Norma, S. Martin, and E. S. S. Elfrides, “Structural elucidation of rabeprazole sodium photodegradation products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 1, pp. 88–93, 2008. View at Publisher · View at Google Scholar
  9. M. Miura, H. Tada, S. Satoh, T. Habuchi, and T. Suzuki, “Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction,” Journal of Pharmaceutical and Biomedical Analysis, vol. 41, no. 2, pp. 565–570, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. El-Gindy, F. El-Yazby, and M. M. Maher, “Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 31, no. 2, pp. 229–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Nakai, Y. Shimamura, T. Kanazawa, S. Yasuda, and M. Kayano, “Determination of a new H+-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance Liquid chromatography,” Journal of Chromatography B: Biomedical Applications, vol. 660, no. 1, pp. 211–220, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. Shirkhedkar and S. J. Surana, “Application of stability-indicating RP-TLC densitometric determination of rabeprazole sodium in bulk drug and pharmaceutical formulation,” Eurasian Journal of Analytical Chemistry, vol. 4, pp. 87–97, 2009. View at Google Scholar
  13. P. B. Raval, M. Puranik, S. J. Wadher, and P. G. Yeole, “A validated HPTLC method for determination of ondansetron in combination with omeprazole or rabeprazole in solid dosage form,” Indian Journal of Pharmaceutical Sciences, vol. 70, no. 3, pp. 386–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. B. H. Patel, B. N. Suhagia, M. M. Patel, and J. R. Patel, “HPTLC determination of rabeprazole and domperidone in capsules and its validation,” Journal of Chromatographic Science, vol. 46, no. 4, pp. 304–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Rahman, Z. Bano, and S. N. H. Azmi, “Quantitative analysis of rabeprazole sodium in commercial dosage forms by spectrophotometry,” Chemical and Pharmaceutical Bulletin, vol. 56, no. 7, pp. 995–1001, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Madhuri, K. B. Chandrasekhar, M. Ramakotaiah, G. Somasekhar, K. Harinadhababa, and K. R. Kumar, “Validation of spectrophotometric determination of Rabeprazole using ferric chloride (FeCl3),” International Journal of Research in Pharmaceutical Sciences, vol. 1, no. 2, pp. 209–211, 2010. View at Google Scholar · View at Scopus
  17. M. M. Gouda, S. Somashekar, P. R. Kumar, and S. M. S. Kumar, “Physico-chemical characterization, UV spectrophotometric analytical method development and validation studies of rabeprazole sodium,” Journal of Chemical and Pharmaceutical Research, vol. 2, pp. 187–192, 2010. View at Google Scholar
  18. F. Shao, J. Sun, G. Wang, H. Xie, X. Zhu, and J. Zhang, “Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats,” Biopharmaceutics and Drug Disposition, vol. 28, no. 4, pp. 177–186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Radi, N. Abd El-Ghany, and T. Wahdan, “Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form,” Farmaco, vol. 59, no. 7, pp. 515–518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. B. H. Patel, B. N. Suhagia, M. M. Patel, and J. R. Patel, “High-performance liquid chromatography and thin-layer chromatography for the simultaneous quantitation of rabeprazole and mosapride in pharmaceutical products,” Journal of Chromatographic Science, vol. 46, no. 1, pp. 10–14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. S. Shweta, D. D. Nilesh, Y. J. Vijay, R. T. Santosh, and V. G. Santosh, “Spectrophotometric simultaneous determination of rabeprazole sodium and domperidone in combined tablet dosage form,” Eurasian Journal of Analytical Chemistry, vol. 3, pp. 236–244, 2008. View at Google Scholar
  22. ICH, Validation of Analytical Procedures: Text and Methodology Q2 (R1), ICH, Geneva, Switzerland, 1996.
  23. The United States Pharmacopoeia, 35, NF 30, vol. 1, United States Pharmacopeial Convention, Rockville, Md, USA, 2012.
  24. U.S. Food and Drug Administration, Dissolution Methods Database, http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_searchresults_dissolutions.cfm?printall=1.
  25. Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office, Washington, DC, USA, 1997.
  26. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations, Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office, Washington, DC, USA, 1997.